Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Rd Tarrytown
NY
10591-6707 United States
Integral Health Asset Management Expands Vera Therapeutics Stake in 2026
Coverage of Integral Health Asset Management's significant share purchase in Vera Therapeutics in early 2026, detailing the transaction's value and the biotech company's upcoming regulatory milestone.
Source: IndexBox Mar 20, 2026
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.
Source: Motley Fool Mar 20, 2026
Wall Street Faces a $5.7 Trillion Triple-Witching Jolt on Friday
Roughly $5.7 trillion in notional options tied to individual US stocks, indexes and exchange-traded funds are set to expire on Friday in the quarterly event that traders have dubbed the “triple-witching” — the largest March expiry in Citigroup Inc. data going back to 1996. The event, which forces traders to close, roll or rebalance positions, has long carried a reputation for triggering abrupt price swings as large pools of derivatives exposure suddenly vanish. This quarter’s...
Source: Bloomberg Mar 19, 2026
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
Source: Zacks Mar 19, 2026
Is Pfizer Inc. (PFE) One of Goldman Sachs Top Healthcare Stocks?
Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target. The bullish stance follows positive phase 2 data on the company’s tri-specific antibody tilrekimig. Trial results showed that the once-a-month inhibitor achieved a placebo-adjusted high
Source: Insider Monkey Mar 15, 2026
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy?
Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Ocular Capital’s Substack. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $774.66 as of March 11th. REGN’s trailing and forward P/E were 18.68 and 18.05, respectively according to Yahoo Finance.
Source: Insider Monkey Mar 15, 2026
- Monoclonal antibodies
- Antibodies production technology
- Bispecific antibodies
- Cholesterol-lowering drugs
- Anti-inflammatory drugs
- Cardiovascular drugs
- Metabolic disease drugs
- Rare disease drugs
- Eye disease drugs
- Protein-based drugs
- Drug formulation technology
- Genetics sequencing equipment
- Chemical reagents for drug development
- Biotechnology research tools
- Antibody purification kits
- Laboratory equipment for drug research
- Microplate readers
- High-throughput screening systems
- Automated cell counters
- Cell culture media
- Drug delivery systems
- Bioreactors for protein production
- Biopharmaceutical manufacturing equipment
- Liquid handling robots
- Genetically-humanized mice
- Antibody engineering software
- Clinical trial management software
- Pharmaceutical packaging materials
- Cold chain logistics services
- Regulatory compliance consulting services
- Monoclonal antibodies for cancer treatment
- Cholesterol-lowering drugs
- Anti-inflammatory drugs
- Cardiovascular disease medications
- Metabolic disease treatments
- Antiviral drugs
- Orphan drugs for rare diseases
- Ophthalmic drugs for eye diseases
- Genetically-humanized mice for antibody production
- Fully-human antibodies
- Bispecific antibodies
- Genetics sequencing services
- Protein-based drug development services
- Velocisuite technology licensing
- Research collaboration services
- Drug development consulting
- Biotechnology research tools
- Pharmaceutical manufacturing equipment
- Chemical reagents for drug development
- Laboratory supplies for biotechnology research
- Clinical trial management software
- Regulatory compliance consulting services
- Quality control testing services
- Packaging and labeling solutions for pharmaceuticals
- Cold chain logistics services for drug distribution
- Medical waste disposal services
- Pharmacovigilance monitoring services
- Patient support programs for medication adherence
- Health economic outcomes research services
IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.
All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.